Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29436946 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1LMNAATMKMT2A | |
| SCHEMBL19451681 | 0.88 | STING1 (0.42) | SMN1; SMN2ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL28413730 | 0.88 | STING1 (0.42) | SMN1; SMN2ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL29405190 | 0.88 | STING1 (0.42) | SMN1; SMN2ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL21643836 | 0.86 | KMT2A (0.41) | SMN1; SMN2ALDH1A1LMNAATMKMT2A | |
| SCHEMBL21643835 | 0.86 | KMT2A (0.41) | SMN1; SMN2ALDH1A1LMNAATMKMT2A | |
| SCHEMBL21643816 | 0.84 | STING1 (0.39) | ALDH1A1LMNAKMT2AMEN1STING1 | |
| SCHEMBL29436967 | 0.84 | STING1 (0.39) | ALDH1A1LMNAKMT2AMEN1STING1 | |
| SCHEMBL19451811 | 0.83 | STING1 (0.38) | ALDH1A1LMNAKMT2AMEN1STING1 | |
| SCHEMBL28606484 | 0.83 | STING1 (0.38) | ALDH1A1LMNAKMT2AMEN1STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-11713317-B2 | Tricyclic heterocyclic compounds as sting activators | INCYTE CORPORATION (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713317-B2 | Tricyclic heterocyclic compounds as sting activators | INCYTE CORPORATION (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713317-B2 | Tricyclic heterocyclic compounds as sting activators | INCYTE CORPORATION (US) | 2023-08-01 | — | — | US | disclosed |
| US-11596692-B1 | PD-L1/STING conjugates and methods of use | INCYTE CORPORATION (US) | 2023-03-07 | — | — | US | disclosed |
| US-11596692-B1 | PD-L1/STING conjugates and methods of use | INCYTE CORPORATION (US) | 2023-03-07 | — | — | US | disclosed |
| US-11427597-B2 | Heteroaryl amide compounds as sting activators | INCYTE CORPORATION (US) | 2022-08-30 | — | — | US | disclosed |
| EP-3802534-B1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS | INCYTE CORP (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3802534-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS | Incyte Corporation (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10947227-B2 | Tricyclic heterocyclic compounds as sting activators | INCYTE CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
| US-10947227-B2 | Tricyclic heterocyclic compounds as sting activators | INCYTE CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
| US-10875872-B2 | Heteroaryl amide compounds as sting activators | INCYTE CORPORATION (US) | 2020-12-29 | — | — | US | disclosed |
| US-10875872-B2 | Heteroaryl amide compounds as sting activators | INCYTE CORPORATION (US) | 2020-12-29 | — | — | US | disclosed |
| WO-2020132582-A1 | STING AGONISTS AND USES THEREOF | NIMBUS TITAN, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200039994-A1 | HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS | INCYTE CORPORATION | 2020-02-06 | — | — | US | disclosed |
| WO-2020028566-A1 | HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS | INCYTE CORPORATION (US) | 2020-02-06 | — | — | WO | disclosed |
| WO-2020028566-A1 | HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS | INCYTE CORPORATION (US) | 2020-02-06 | — | — | WO | disclosed |
| US-20200039994-A1 | HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS | INCYTE CORPORATION | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11596692-B1 | PD-L1/STING conjugates and methods of use | STING1, PDCD1LG2, CD274 | SMN1; SMN2 2719/4885ALDH1A1 3719/4885LMNA 2058/4885 |
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | STING1, PDCD1LG2, CD274 | SMN1; SMN2 2719/4885ALDH1A1 3719/4885LMNA 2058/4885 |
| US-11713317-B2 | Tricyclic heterocyclic compounds as sting activators | STING1, MAVS, IRF3 | SMN1; SMN2 4319/4885ALDH1A1 4780/4885LMNA 3027/4885 |
| US-10875872-B2 | Heteroaryl amide compounds as sting activators | STING1, MAVS, IRF3 | SMN1; SMN2 4268/4885ALDH1A1 4823/4885LMNA 3795/4885 |
| US-10947227-B2 | Tricyclic heterocyclic compounds as sting activators | STING1, MAVS, IRF3 | SMN1; SMN2 4319/4885ALDH1A1 4780/4885LMNA 3027/4885 |
| US-11427597-B2 | Heteroaryl amide compounds as sting activators | STING1, MAVS, IRF3 | SMN1; SMN2 4268/4885ALDH1A1 4823/4885LMNA 3795/4885 |
| US-20200039994-A1 | HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS | STING1, MAVS, IRF3 | SMN1; SMN2 4268/4885ALDH1A1 4823/4885LMNA 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.